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SUMMARY
With rising health care costs, often health research is viewed as a major cost driver, calling to question the role and 
value of provincial funding of health research. Most agree that the quality of healthcare provided is directly linked 
to our ability to conduct quality research; however currently there is little empirical evidence supporting the link 
between engagement in health research and healthcare performance. In Canada this has resulted in funding for 
health research that varies over time and between provinces. 
While medical knowledge is a public good, we hypothesize there are local benefits from health research, such as 
the attraction of a specialized human capital workforce, which fosters a culture of innovation in clinical practice. To 
address this question, we look at whether health outcomes are impacted by changes in provincial research funding 
in Alberta compared to other provinces. Provincial funding for medical research, which varies greatly over time 
and among provinces, is used as a proxy for medical treatment inputs. Trend rates of reduction in mortality from 
potentially avoidable causes (MPAC) (comprised of mortality from preventable causes (MPC) and mortality from 
treatable causes (MTC)), are used as a proxy health outcome measure sensitive to the contributions of technological 
progress in medical treatment.
Our analysis suggests that investment in health research has payback in health outcomes, with greater improvements 
in the province where the research occurs. The trend declines seen in age standardized MPAC rates in different 
Canadian provinces may be impacted by shifts in provincial research funding investment, suggesting that 
knowledge is not transferred without cost between provinces. Up until the mid-1980s, Alberta had the most rapid 
rate of decline in MPAC compared to the other provinces. This is striking given the large and unique investment in 
medical research funding in Alberta in the early 1980s through AHFMR, the only provincial health research funding 
agency at the time. However in recent years, Alberta’s rate of decrease in MPAC has occurred at a rate slower than 
the other provinces (British Columbia, Ontario or Quebec) with provincial medical research funding. This is striking 
at a population level, where Alberta’s failure to achieve a reduction in age standardized rates of MTC comparable 
to British Columbia, Ontario or Quebec after 1985 represents 240 unnecessary deaths in 2011 and 48,250 Potential 
Life Years Lost worth around $4.8 billion.
The findings from our study suggest that some of the divergence in the rates of reduction in MPAC between 
provinces may be due to beneficial changes in institutional structure and human capital, resulting in differences 
across provinces in the capacity to adopt new effective healthcare innovations. While health indicators such as 
MPAC are the result of complex interactions between the patient, treatment and the healthcare system, as well as 
socioeconomic and demographic factors, this analysis suggests that a different capacity for health research within 
the provinces impacts health outcomes. The findings from this analysis are limited by the lack of data related to 
research funding and the health research workforces within provinces. 
This analysis has important implications for health research policy and funding allocations, suggesting that decision 
makers should consider the long-term impact provincial funding for health research has on health outcomes. This 
study also highlights the lack of longitudinal public data available for provincial health research funding. This 
information is critical to inform future health research policy.
The SPP discussion papers are circulated for discussion and comment purposes. They have not been peer reviewed or been 
subject to the review by the SPP editorial process that accompanies SPP Research Papers.
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1INTRODUCTION
“ Advances in medical knowledge, borne of medical research, are a main source of longer 
and healthier lives. The value of gains in health over the past half century appears to have 
far outstripped the comparatively modest investments in medical R&D, and it is plausible 
that future investments can yield “extraordinary returns.”1
What is the value of medical and health research for the province of Alberta? Since the 
creation of the Alberta Heritage Foundation for Medical Research (AHFMR) in 1979, 
Alberta has been a province that has been a major investor in medical research. However, 
over AHFMR’s 35 years of existence there has been an on-going debate as to why research 
should be supported, what research should be supported, and more recently, whether 
medical and health research should be supported in Alberta to the extent that it is. Research 
support through Alberta Health Services since 2009 has eroded. AHFMR was re-purposed 
into Alberta Innovates Health Solutions (AIHS) with a shift from funding researchers 
in university faculty positions and trainees to funding research projects, particularly 
research with commercial potential. Most recently in the Alberta Budget for 2015, former 
Premier Prentice had scheduled a 30% reduction in the AIHS budget representing a major 
contraction of research resources for university researchers in the province. 
When Stephen Duckett was appointed the CEO of Alberta Health Services in 2009 the 
role and value of health research in the province was an open question. At the time, Globe 
and Mail columnist Andre Picard characterized Alberta’s health care system as the best, 
most innovative health system in Canada over the 2000s because of regionalization of 
system management that contributed to strong alliances between university researchers and 
health regions. Alternative payment plans for physicians encouraged a balance of research, 
teaching and patient care.2 The perceived success of Alberta’s regionalized structure and 
its stimulus for synergies between research and services for patients was at risk with the 
creation of a single authority and a mandate to control costs in the immediate term. Duckett 
indicated that he only intended to fund research with “measurable results” and wanted 
to import the best ideas and practices from around the globe to front line health care in 
Alberta. Picard predicted that the Duckett direction would lead to Alberta’s research stars 
leaving for other provinces.3
1 Murphy, Kevin M., and Topel, Robert H., eds. Measuring the Gains from Medical Research: An Economic Approach. 
Chicago, IL, USA: University of Chicago Press, 2010. ProQuest ebrary. Web. 24 May 2015.
2 “Alberta has, in the past decade or so, created the best, most innovative health system in Canada. Regionalization 
allowed health authorities to shape services to local needs, created better continuity of care, made the health system more 
responsive, improved public health and led to strong alliances between university researchers and health regions.” André 
Picard’s Second Opinion. The future of medicare is in his hands. Globe and Mail. Published Thursday, Jun. 11 2009. http://
www.theglobeandmail.com/life/health-and-fitness/the-future-of-medicare-is-in-his-hands/article786786/ 
3 “He speaks of physicians primarily delivering front-line care, which suggests that Alberta’s alternative payment plans 
that encourage balancing research, teaching and patient care are in the crosshairs. He wants to fund only research with 
“measurable results” - presumably immediately. Other provinces must be licking their chops at the prospect of wooing back 
all the research stars they lost to Alberta in recent years.” André Picard’s Second Opinion. The future of medicare is in his 
hands. Globe and Mail. Published Thursday, Jun. 11 2009. http://www.theglobeandmail.com/life/health-and-fitness/the-
future-of-medicare-is-in-his-hands/article786786/ 
2To address these conflicting viewpoints, we examine if health research in Alberta is 
better for patient outcomes. While a link between research engagement and healthcare 
performance is feasible, there is currently little in the way of empirical evidence. A 
systematic review suggested that when clinicians and health-care organisations engage 
in research there is the likelihood of a positive impact on health-care performance.4 The 
Duckett/Prentice direction of using Alberta monies for research with measurable, or 
perhaps commercializable benefit, presumes that the production of knowledge locally is 
unnecessary since the diffusion of knowledge and best practices for patient care can be 
costlessly imported to the province. If this is the case, then the gamble with monies for 
health research being re-allocated to front line care is that there is no measurable negative 
effect of the changes to the health research workforce on patient care in the province and 
ultimately the health of Albertans. Is there any evidence to support this expectation?
We specify the Duckett/Prentice position as a testable hypothesis that the presence, size and 
quality of the health research workforce are uncorrelated with patient health outcomes. This 
assumes that the market for ideas and diffusion of knowledge is frictionless in the sense 
that once ideas and knowledge are in the public domain, they are available for adoption. It 
follows that the impact of ideas and knowledge is independent of where the ideas originate 
and who produces them. The policy concern in this state of the world is ensuring that 
the conditions that create ideas and knowledge are such that the production of global 
knowledge is maximized.5 
The alternative hypothesis is that the market for ideas and knowledge has frictions, which 
means that knowledge is not transferred without cost from producers to users. Diffusion 
theory identifies key components of the innovation process to include the innovation, the 
social system through which the innovation moves, the communication channels of that 
system and the adoption of the innovation by the intended recipients.6 This suggests that 
the ability for patients to benefit from knowledge production requires local production 
and/or clinicians who seek out knowledge and apply it locally. Even though ideas and 
knowledge are freely available to the world, there are still local benefits from the attraction 
of the specialized human capital workforces which foster a culture of innovation in clinical 
practice. Research funding and opportunities for clinicians may attract a higher quality 
physician, or a different culture of physicians, that leads to better treatment, better practices 
and innovation in service delivery. 
Testing the Duckett/Prentice hypothesis requires the selection of available measures of 
health outcomes thought to be correlated with the presence or absence of health researchers. 
It is not obvious what measures are available to use. Health and patient outcomes will be 
influenced by many factors, many of which have nothing to do with medical treatment or 
health researchers. There is little in the way of available data for health outcomes that can 
4 
Hanney S, Boaz A, Jones T, Soper B. Engagement in research: an innovative three-stage review of the benefits for health-
care performance. Health Serv and Deliv Res. 2013;1(8).
5 
Governments may have a secondary goal of seeking to capture the rents/profits from knowledge production through the 
promotion of research with commercial potential. This objective is more for economic diversification than improving health 
outcomes in the local population.
6 Rogers EM. Diffusion of innovations, 4th ed. New York: Free Press, 1995.
3be directly tied to health research, resulting in the use of proxy measures – health outcomes 
that change in ways that may signal the influence of local health research findings and 
health researcher personnel.
Advances in medical knowledge can be considered as “technological progress” in that the 
increase in the stock of knowledge improves health outcomes for given amounts of medical 
treatment inputs. In this study, we use trend rates of reduction in mortality from potentially 
avoidable causes as a health outcome measure that will be sensitive to the contributions 
of technological progress in medical treatment. We use a mortality measure because it 
is estimated that about one-third of improvements seen in mortality over the past few 
decades comes from high-tech invasive treatment, one-third from low-tech pharmaceutical 
innovation and the final third from behavioural changes such as reduced rates of smoking.7 
While these proportions can be debated, it is clear that medical research is at the heart of all 
of these factors impacting health outcomes. 
Measures of avoidable mortality 8 are useful in their ability to capture causes of death where 
the mechanisms of mortality reduction are known as alterable with decision maker actions 
and potentially sensitive to the presence of a health research workforce and a culture of 
innovation. Estimates of avoidable mortality in Canada are used as a potential measure of 
health care system performance that “serves to focus attention on the portion of population 
health attainment that can potentially be influenced by the health system.”9 Mortality 
rates from avoidable causes have many determinants; 10 however the diffusion of new 
knowledge into clinical practice will affect the rate of decline in these rates. The impact of 
health research on avoidable mortality can be inferred from trend changes in this outcome 
measure. 
In this study we look at whether avoidable mortality is impacted by this shift in provincial 
research funding in Alberta compared to other provinces. Provincial funding for medical 
research, which varies greatly over time and among provinces, is used as a proxy for 
medical treatment inputs.11 As a large and rapidly developed medical research intervention, 
AHFMR experienced several unanticipated fiscal shocks and periodic shifts in its mission 
that were not clearly related to concerns or even awareness over health outcomes in the 
Alberta population. This “plausibly exogenous” variation in research inputs affords us 
an opportunity to infer the causal impact of medical research investment on avoidable 
mortality outcomes.
7 Cutler, David M. and Kadiyala, Srikanth. The Return to Biomedical Research: Treatment and Behavioral Effects. Chapter 
4 from Measuring the Gains from Medical Research: An Economic Approach. Chicago, IL, USA: University of Chicago 
Press, 2010.
8 Deaths that could potentially have been avoided through disease prevention or healthcare services. Canadian Institute for 
Health Information. Health Indicators 2012. Ottawa, Canada: Canadian Institute for Health Information; 2012.
9 Avoidable mortality is apportioned into mortality from preventable deaths and mortality from treatable causes. Canadian 
Institute for Health Information (2012) Health Indicators 2012 (Ottawa: CIHI). 
10 including access to treatment, health behaviors, environmental conditions and technical change in medical treatment, 
the levels of the rates will differ across locales and it will not be possible to attribute an impact of medical research in 
explaining these cross sectional differences
11 Murphy, Kevin M., and Topel, Robert H., eds. Measuring the Gains from Medical Research: An Economic Approach. 
Chicago, IL, USA: University of Chicago Press, 2010. ProQuest ebrary. Web. 24 May 2015.
4Our analysis in this study demonstrates that research has payback for Albertans in terms 
of improved health outcomes. The trend declines seen in age standardized MPAC rates in 
different Canadian provinces may by impacted by shifts in provincial research funding 
investment. When interpreting the changes in funding allocation and mandate for AHFMR 
throughout its 30 years, the difference in mortality from potentially avoidable causes 
(MPAC) in Alberta compared to other provinces suggests that knowledge is not transferred 
without cost from producers to users, as was postulated in the Duckett/Prentice hypothesis. 
ALBERTA’S INVESTMENT IN MEDICAL RESEARCH 
The unique features of AHFMR funding in Alberta compared to other provinces suggests 
a “natural experiment” style of analysis may be appropriate to look at the impact of health 
research funding on health outcomes. Natural experiments are opportunities to assess 
causal influences on outcomes of interest arising from plausibly exogenous variation in 
determinants of interest. One of the main advantages in using a natural experiment to 
test our hypothesis is the ability to minimize effects caused by selectivity. 12 We look at 
AHFMR over its history as a natural experiment that provides an opportunity to identify 
the effect of a health research workforce on health outcomes of Albertans. 
Among the provinces, Alberta was unique in its early establishment and investment 
in medical research with AHFMR being the only provincial medical research-funding 
agency prior to 1999, when Quebec and then BC established provincial agencies.13 Figure 1 
presents the expenditure information in nominal dollars from Alberta, Quebec, Manitoba, 
Saskatchewan and British Columbia medical research funding agencies since the 1980s. 
The stated AHFMR purpose of investing in medical research was to improve the quality 
of health care in Alberta by attracting high quality researchers and trainees to Alberta14 as 
well as support facility upgrades and renovations to improve the availability and adequacy 
of space for medical research. 
The AHFMR investment attracted world-class scientists to Alberta and was thought to have 
a real impact on the health research culture, as described by Dr. Cy Frank in 1989, “When 
I graduated in orthopedic surgery I reached the great fork in the road- whether to pursue 
these things and try to solve problems or simply apply technology to the clinical setting. 
It didn’t take me long – about one second- to decide the excitement is in answering the 
questions. I knew it could be done and I started believing maybe it could be me. AHFMR 
was the major pathway to fulfilling these dreams.”15 By 1995 Alberta was a leader among 
12 In a natural experiment the treatment is random and not by design. To state it differently, the treatment is administered “by 
nature” and not by the experimenter. Natural experiments can be helpful when a well- defined subpopulation experiences a 
change in treatment. How Economics Shapes Science. Paula Stephan. 2012
13 Note that Ontario doesn’t have one central comparable provincial agency and weren’t included in this comparison
14 In the 1992 AHFMR annual report it was noted that high housing costs in Alberta was one factor that inhibited the 
recruitment of new personnel to Alberta. 
15 On the edge of discovery. Third Triennial Report. 1989. AHFMR. 
5Canadian provinces for provincial funding of medical research and was identified as one of 
the top 10 medical research centers in North America (Figure 2).16 
As a large and rapidly developed medical research intervention, AHFMR experienced 
several unanticipated fiscal shocks and periodic shifts in its mission that were not clearly 
related to concerns or even awareness over health outcomes in the Alberta population. Less 
favorable financial market conditions squeezed the asset value of the endowment and the 
annual income that it was generating in the 1990s (Figure 3) 17 resulting in reductions in 
AHFMR funding (Figure 4) and the size of the medical research workforce supported by 
AHFMR (Figure 5).18 
With the financial challenges came pressures from the provincial government for AHFMR 
to shift some of its emphasis on biomedical research to health and clinical research which 
were considered to be closer to front line care of Albertans and more profitable through 
commericalization.19 Eventually, in response to these financial pressures AHFMR 
broadened its mandate to include applied health research.20 This culminated in AIHS in 
2010, developed with the goal of pursuing opportunities and delivering support for health 
research and innovation that creates more health and socio-economic benefits for Albertans 
rebalancing “curiosity led” to “solutions-driven” research. 21 22 This move from AHFMR’s 
early mandate supporting talented researchers towards AIHS’s goals of supporting solution 
driven projects with potentially commercializable outcomes, would suggest that the beliefs 
of the earlier era in the spillover benefits for patient care from basic research was not 
16 Window on Future Health. Alberta Heritage Foundation For Medical Research Annual Report. Edmonton 1995. 
17 Endowment Fund Net Assets on a cost basis had been maintained at a steady level; however market or realizable value 
was reduced due to the high level of interest rates in Canada in the late 1980’s. This depressed the market value of the 
government and government-guaranteed debt instruments, which were a significant part of the Endowment Fund assets. 
In 1990 the $500 million in the endowment looked healthy compared to the $300 million initial value; however its value in 
1980 dollars was only $278 million. Inflation had continuously decreased the purchasing power of the endowment’s assets. 
We’re learning a few secrets. Alberta Heritage Foundation for Medical Research Annual Report. Edmonton 1991.
18 The fourth (1990/93) triennial report of the AHFMR international review board details the large contraction in health 
research personnel from 1986 to 1992, particularly amongst trainees and fellows, and the scheduled further reductions in 
supported faculty positions, particularly at the University of Calgary. As of 1993, 220 investigators had been recruited to 
AHFMR funded institutional positions since 1980, 72% of which (159) were still supported by the foundation in 1993. “42 
left the left the system spontaneously” The report of the 1993 International Board of Review. A review of the operation of 
the Alberta Heritage Foundation for Medical Research for the period of 1987-1993. Edmonton 1993.
19 Former Alberta Premier Don Getty appointed Lou Hyndman to chair the Rainbow Commission to examine health care 
services and costs in the province. The commission identified health priorities for Alberta in their Rainbow Report, to 
which the government responded with the Partners in Health report published in 1991. The reports identified that there 
was a shortage of well-trained clinical investigators and a need for more support systems for funding clinical researchers/
physicians with basic research training who can help take new knowledge to the bedside. Rainbow Report, Premier’s 
Commission on Future Health Care for Albertans, Hyndman, Louis D. 1989. Partners in health: the Government of 
Alberta’s response to the Premier’s Commission on Future Health Care for Albertans. Government of Alberta. Edmonton 
1991. Push towards commercialization outlined in a White Paper called “Proposals for an Industrial and Science Strategy 
for Albertans 1985-1990”
20 Backing a range of applied health care related research in cancer, diabetes, arthritis, infections, ulcers, Alzheimer’s disease, 
high blood pressure and maternal and baby care. It’s nice to know… Alberta Heritage Foundation For Medical Research 
1993-1994 Annual Report. Edmonton 1994.
21 AIHS was interested in focusing on “the strengths of teams of people to tackle complex, real life problems” Alberta 
Innovates Health Solutions Annual Report. 2011-2012. 
22 This involved the closure of some programs and the launch of an implementation process to develop new initiatives focused 
on the new mandate. Most notable in the transition, AIHS closed the AHFMR Independent Investigator program to new 
entry and implemented a final cohort of 34 seven-year AHFMR Investigator Awards from the September 2009 competition. 
Alberta Innovates Health Solutions Annual Report 2012-2013. 
6shared. This health research policy shift in Alberta suggests that funding for biomedical 
research carries the opportunity cost of less innovation and improvement in patient care 
in Alberta. To test if this is the case, empirically the goal is to measure the contribution of 
technological progress to the improvement in health outcomes such as reduced death rates. 
Figure 1. Provincial Health Research Funding Agencies’ Expenditures on Scientific Affairs (excluding operating 
costs) by 2015 Purchasing Power. Alberta was unique in its early establishment and investment in medical research 
with AHFMR being the only provincial medical research-funding agency prior to 1999. Once funding agencies were 
developed in Quebec and BC, expenditures on health research rose steadily in the early 2000s while funding in 
Saskatchewan and Manitoba remained relatively stable at a much lower level. One impact of this other provincial funding 
was on the competition for federal funding. For example the development of the Michael Smith Foundation resulted in 
a greater percentage of CIHR funding being attracted to BC (9% to 14 %) between the years 2001 to 2012 compared 
to Alberta (12% to 9%), respectively.23 Expenditure information from annual financial statements from AHFMR/AIHS, 
Michael Smith Foundation, Saskatchewan Health Research Foundation, Manitoba Health Research Foundation and Fonds 
de Recherché Sante since 1981. Ontario was not included as there are several different agencies.
23 British Columbia Health Research Strategy. Health Research in BC. An overview. July 2013
7Figure 2. Timeline of AHFMR activity and mandate. AHFMR was established to improve the quality of health care 
in Alberta by attracting high quality researchers to Alberta. Prior to AHFMR Alberta had a shortage of researchers 
considered to be competitive for federal health research funding, which was thought to negatively impact the quality 
of medical education and the application of new knowledge to patient care.24 With the development of AHFMR, 
Alberta’s medical research began to develop national and international recognition for work in better understanding 
the mechanisms of disease as it applies to prevention, early detection and management. There was also a growing push 
towards technology transfer through commercializing research.25 These dual objectives remained a source of debate 
throughout the lifespan of AHFMR. In 2008 AHFMR transformed its approach to focus on how health research and 
innovation are linked, with the objective of capturing the benefits of health research for the health system and the health 
and wellbeing of Albertans.26 The redesign27 resulted in Alberta Innovates Health Solutions (AIHS) developed with the 
goal of taking advantage of the AHFMR legacy, but created more health and socio-economic benefits for Albertans 
rebalancing “curiosity led” (basic biomedical ) to “solutions-driven” (health services and population health) research. 28, 29 
Information compiled from AHFMR annual reports 1981 to 2009 and AIHS annual reports 2010 to 2014.
24 
A review of the operations of the Alberta Heritage Foundation for Medical Research for the period 1980-1986. Second 
Triennial Report Part II. Alberta Heritage Foundation for Medical Research. Edmonton 1986.
25 As outlined in a White Paper called “Proposals for an Industrial and Science Strategy for Albertans 1985-1990”
26 Alberta Innovates Health Solutions Annual Report. Edmonton 2010-2011.
27 Guided by the Alberta Health Research and Innovation Strategy (AHRIS)Alberta Health and Research Innovation Strategy. 
Government of Alberta Innovation and Advanced Education. Edmonton 2010.
28 AIHS was interested in focusing on “the strengths of teams of people to tackle complex, real life problems” Alberta 
Innovates Health Solutions Annual Report. 2011-2012. 
29 This involved the closure of some programs and the launch of an implementation process to develop new initiatives focused 
on the new mandate. Most notable in the transition, AIHS closed the AHFMR Independent Investigator program to new 
entry and implemented a final cohort of 34 seven-year AHFMR Investigator Awards from the September 2009 competition. 
Alberta Innovates Health Solutions Annual Report 2012-2013. 
8Figure 3. Alberta Heritage Foundation for Medical Research Endowment fund annual transfers. The AHFMR was 
established in 1979 and funded with a $300 million endowment expected to generate $30 million annually to strengthen 
Alberta’s medical research capability. Transfers from the AHFMR Endowment Fund peaked by 1989. Construction of 
two buildings to house multi-disciplinary AHFMR teams and the less favorable financial market conditions squeezed the 
asset value of the endowment and the annual income that it was generating, resulting in a decline in transfers after 1989. 
Endowment Fund net assets on a cost basis had been maintained at a steady level; however market or realizable value 
was reduced due to the high level of interest rates in Canada in the late 1980’s. The trustees of the foundation agreed 
that the endowment would require supplementation of the AHFMR endowment with the rate of growth in spending on 
research expenditures and infrastructure, however this did not occur. From 1997 to 2003 transfers increased. By 2004 
the Foundation was once again at a tipping point created by a decline in the value of the Foundation’s endowment 
due to a combination of a lowered rate of return on investment, less purchasing power of the investment income as a 
result of continuing inflation in health sector salaries and other costs and the Foundation’s ongoing salary support of 
more increasingly senior research personnel.30 In the 2005 spring session of the Alberta Legislature, the government 
announced its commitment to increase the endowment for AHFMR by an additional $500 million over 3 years. By 
2009 AIHS was created and a total of $118 million from the AHFMR Endowment Fund was approved in the February 
2011 budget of the Government of Alberta to be allocated to AIHS over eight years. Information compiled from AHFMR 
annual reports 1981 to 2009.


















Figure 4. Alberta Foundation for Medical Research expenditure on scientific affairs (administration and building 
costs excluded). The initial AHFMR objective was to both support the recruitment of medical researchers and trainees31 
as well as support facility upgrades and renovations to improve the availability and adequacy of space for medical 
research. From 1985 to 1990 the foundation projected to spend $300 million, including $54.8 million for two medical 
research buildings in Edmonton and Calgary.32 Expenditures increased until 1989 when expenditures sharply declined 
as inflation continuously decreased the purchasing power of the endowment’s assets. 33 In a long term plan for growth 
of the foundation in the early 90’s, it was determined that the AHFMR objectives would require supplementation of the 
foundations endowment however this did not occur. AHFMR then broadened its mandate from biomedical research 
to include health research.34 Between 1992 and 1996 spending on health research quadrupled from $208,615 to 
$906,087, 3% of AHFMR expenditures35 By 1995 Alberta was a leader among Canadian provinces for provincial funding 
of medical research and was identified as one of the top 10 medical research centers in North America.36 However by 
2004 low rates of return on investment and large salary and other expenditure demands put AHFMR in financial trouble 
that threatened its sustainability. AHFMR was redesigned to become AIHS in 2009 with an emphasis placed on the 
application of knowledge to improve health, health systems, and health care. Information compiled from AHFMR annual 
reports 1981 to 2009.
31 In the 1992 AHFMR annual report it was noted that high housing costs in Alberta was one factor that inhibited the 
recruitment of new personnel to Alberta. 
32 
Alberta Heritage Foundation for Medical Research 5th Annual Report. Edmonton 1985.
33 We’re learning a few secrets. Alberta Heritage Foundation for Medical Research Annual Report. Edmonton 1991.
34 Backing a range of applied health care related research in cancer, diabetes, arthritis, infections, ulcers, Alzheimer’s disease, 
high blood pressure and maternal and baby care It’s nice to know… Alberta Heritage Foundation For Medical Research 
1993-1994 Annual Report. Edmonton 1994.
35 In 1995 AHFMR entered a collaborative agreement with Alberta Health to conduct health technology assessments for 
Alberta, administer health research funds in the Department and coordinate the development of a provincial health 
research agenda. This resulted in additional revenue for the 1995/96 period in excess of $2.2 million. AHFMR also took on 
administering the Medical Innovation Program ($500 000 in 1996) on behalf of the Minister of Economic Development and 
Tourism, targeted at funding early stages for commercial development of medical and health related technologies. These 
funds contributed to the growth in AHFMR funding in the late 1990s with the Medical Innovation Program in excess of $4 
million in funding and the Health Research Collaboration in excess of $8 million in funding. Progression and Excellence. 
Alberta Heritage Foundation for Medical Research Triennial Report Edmonton 1999. Crossing the Gap. Alberta Heritage 
Foundation for Medical Research Triennial Report. Edmonton 1996, 
36 Window on Future Health. Alberta Heritage Foundation For Medical Research Annual Report. Edmonton 1995. 
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Figure 5. AHFMR Scientists, fellows and students based on salary award allocations. Developing and supporting high 
quality researchers was a priority for AHFMR. In 1986 the international review board supported the Foundation’s target 
of a steady state of 180 to 200 Scholars. 37 By 1995, AHFMR supported 109 AHFMR Scientists (11), Scholars (92) and 
clinical investigators (6). 38 These positions at the U of A represented 14% of the medical school’s 250 full time equivalent 
faculty and 27% of the University of Calgary’s 240 medical school’s full time equivalent faculty positions. Over 70% of 
trainees and 50% of the medical researchers were attracted to Alberta from outside the province and former Albertans 
who returned to the province. With the decreased expenditure in the 90’s the international review board stated that 
the expectation moving forward was that the personnel support positions should be capped at 140 to 150. 39 In the 
late 90s the number of career biomedical and health researchers receiving AHFMR support began to rise from the 
dramatic decrease seen in the late 80s. Trainees funded by AHFMR increased slowly, although the number of fellowships 
remained under half of the level seen in the 80s.40 Information compiled from AHFMR annual reports 1981 to 2009.




Not only was this new steady state target below the 200 supported by the IBR in 1986, the high proportion of scientists 
recruited since 1980 still receiving AHFMR support suggests that retention of established scholars was a priority over the 
recruitment of new scientists. 
40 Alberta Heritage Foundation for Medical Research International Board Review. Edmonton 2004.
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DOES PROVINCIAL HEALTH RESEARCH FUNDING IMPACT MORTALITY RATES?
Over the past 30 years Canada has seen steady advances in reducing the national rate of 
avoidable mortality in half from 373 to 185 per 100,000 in 1979 and 2008, respectively.41 
The overall trend in reductions of mortality from avoidable causes in Canada has continued 
largely without interruption; however between provinces and territories the distribution 
of avoidable mortality is varied. Using fitted time trends for mortality from potentially 
avoidable causes (MPAC) comprised of mortality from preventable causes (MPC) and 
mortality from treatable causes (MTC), we look at structural breaks in the trend decline in 
mortality by province. These mortality rates are age standardized per 100,000 people.
In analyzing the impact of Alberta research funding on MPAC, we use Quebec, Ontario 
and British Columbia as comparator provinces with strong provincial research funding 
agencies and Saskatchewan and Manitoba counterfactual (supporting the Duckett/ Prentice 
hypothesis) provinces without much provincial research funding. We look at the impact of 
health research funding by attributing trend declines in age standardized MPAC rates that 
are not explained by changes in medical treatment inputs such as per capita health spending 
and numbers of physicians. 
Overall, the provinces with the fastest and steadiest rates of decline in MPAC and MTC are 
also the provinces that have the majority of federal research funds from CIHR (Ont, Que, 
BC, AB), suggesting federal research funding may have an impact on this health outcome 
measure. Quebec, Ontario and BC will dominate the Canadian trends by virtue of their 
share of total Canadian population. The prairie provinces (particularly Saskatchewan and 
Manitoba) have slower rates of decrease than the other five provinces since 1979 and now 
have some of the highest avoidable mortality death rates in the country42 (Figure 6 and 
Figure 7). 
Up until the mid-1980s, Alberta had the most rapid rate of decline in MPAC and MTC 
compared to the other provinces. This is striking given the large and unique investment 
in medical research funding in Alberta in the early 1980s through AHFMR (Figure 2 and 
3). While it is unlikely that biomedical research would have such an immediate impact on 
a health outcome like MPAC, it is possible that the attraction of world-class researchers 
and clinician scientists to Alberta impacted MPAC. In 1986 there is a structural break for 
both MPAC and MTC in AB, where the rate of decrease comes closer to Ontario, Quebec, 
British Columbia and Manitoba. This transition point for AB maps with the dramatic 
reduction in transfers from Foundation and expenditure on research and personal in Alberta 
(Figure 3 and 4). It is possible that the shift in mandate and focus of AHFMR may have had 
a role in the reduced improvements in the rate of MPAC decline (Figure 2). By the mid-
1990s the decrease in MTC in Alberta moves closer to Saskatchewan and Manitoba, which 
lags that of Quebec, Ontario and British Columbia, in 1994 by 10 per cent (Figure 7). 
41 Canadian Institute for Health Information (2012) Health Indicators 2012 (Ottawa: CIHI).
42 Pi L, Gauvin FP, Lavis JN. Issue Brief: Building Momentum in Using the Avoidable Mortality Indicator in Canada. 
Hamilton, Canada: McMaster Health Forum, 15 February 2013.
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For Alberta another setback occurs around 2000 where the rate of decrease in MPAC and 
MTC occurs at a rate slower than the other provinces with provincial medical research 
funding agencies (Quebec, Ontario and BC). Notably this was also around the time CIHR 
was introduced; suggesting again that federal funding has an impact on MPAC. Alberta’s 
trend decline was the best of the three Prairie Provinces, however since the early 2000s the 
gap between Alberta and Quebec, Ontario and British Columbia has not closed. 
In this analysis, BC is a good comparator province to Alberta with roughly similar 
population sizes and a similar health research-funding agency (Michael Smith Foundation). 
Despite the similarities between Alberta and BC, in 2011 Alberta had 21 and 6.8 more 
deaths per 100,000 people from MPAC and MTC, respectively compared to BC. At the 
population level, this means Alberta has 850 and 62.2 deaths per year that could have been 
avoided if Alberta had matched BC’s trend in MPAC and MTC respectively. Compared 
to Saskatchewan as a counterfactual, in 2011 Alberta had 62.2 and 15.9 fewer deaths per 
100,000 from MPAC and MTC causes respectively. At the population level, Alberta would 
have 2,489 and 635 more deaths per year if it had matched Saskatchewan’s slower rate of 
MPAC and MTC reduction, respectively (Figure 6). 
Notably, by 2011 the gap between the Prairie Provinces and Ontario, Quebec and BC 
doubled. Reductions in MTC in Saskatchewan lagging British Columbia’s rates by 
approximately 20 years, while Manitoba and Alberta’s lags from BC are around 10 years. 
In terms of Potential Life Year’s Lost, Saskatchewan’s lag in MTC causes represents 1,540 
lost life years in 2011.43 If a life year is worth $100,00044, the value of this mortality gap is 
$154,000,000. Alberta’s failure to achieve a reduction in age standardized rates of MTC 
comparable to British Columbia, Ontario or Quebec after 1985 represents 240 unnecessary 
deaths in 2011 and 48,250 Potential Life Years Lost worth around $4.8 billion.
43 if Saskatchewan had matched BC’s rate of decline in age standardized rates of mortality from treatable causes after 1994, 
Saskatchewan would have had 8 per 100,000 population lower mortality rate in 2011, or 80 fewer deaths from treatable 
causes.
44 
Are we finally winning the war on cancer? Cutler, D.M. Journal of Economic Perspectives Volume 22 Number 4 Fall 2008. 
Pg 3-26.
13
Figure 6. Fitted time trends by time period for Mortality from Potentially Avoidable Causes (MPAC) per 100,000 
people. Values indexed as a percentage of 1979’s MPAC rates. We use Quebec, Ontario and British Columbia 
as comparator provinces with strong provincial research funding agencies and Saskatchewan and Manitoba as 
counterfactuals. Quebec, Ontario and British Columbia have the fastest and steadiest rates of decline in MPAC. Alberta 
MPAC declines at the fastest rate in the 1980s. Alberta’s trend decline in MPAC since the early 2000s has slowed 
compared to Quebec, Ontario and British Columbia. (MPAC data from CIHI)
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Figure 7. Fitted time trends by time period for mortality from treatable causes (MTC) per 100,000 people. Values 
indexed as a percentage of 1979’s mortality from treatable causes rate. We use Quebec, Ontario and British Columbia 
as comparator provinces with strong provincial research funding agencies and Saskatchewan and Manitoba as 
counterfactuals. Quebec, Ontario and British Columbia have the fastest and steadiest rates of decline in MTC. Alberta 
MTC declines at the fastest rate in the 1980s. By the mid-1990s the decrease in MTC in Alberta moves closer to 
Saskatchewan and Manitoba, which lags that of Quebec, Ontario and British Columbia, in 1994 by 10 per cent. Alberta’s 
trend decline in MPAC since the early 2000s has slowed compared to Quebec, Ontario and British Columbia. (MTC data 
from CIHI)
HEALTH RESEARCH IMPACTS HEALTH OUTCOMES
The findings from our study suggest that some of the divergence in the rates of reduction 
in MPAC between provinces may be due to differences across provinces in the capacity 
to adopt new effective interventions and/or differential access to the treatments and 
interventions. This supports findings from a recent UK study which found an association 
between level of research activity in NHS Trusts and risk-adjusted mortality.45 While 
health indicators such as MPAC are the result of complex interactions between the patient, 
treatment and the healthcare system, as well as socioeconomic and demographic factors, 
this analysis suggests that that different capacity for health research within the provinces 
has an impact. The Duckett/Prentice hypothesis suggests that local investments in health 
research are inefficient, as the best ideas and practices from around the globe can be 
imported to front line health care in Alberta. The inter-provincial trends describing MPAC 
45 Ozdemir B.A., Karthikesalingam A., Sinha S., Poloniecki J.D., Hinchliffe R.J., Thompson M.M., Gower J.D., Boaz A., Holt 
P.J.E. Research activity and the association with mortality. PLOS ONE. Feb 26;10(2).
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are puzzling if the Duckett/Prentice theory holds. If there were no local benefits to research, 
we would expect no differences across provinces in the MPAC regardless of differences in 
medical innovation capacity. 
Contrary to this hypothesis, the variance in MPAC across provinces suggests that the 
investment needs to occur locally in provinces. Investment of CIHR and provincial funding 
agency dollars seems to impact MPAC rates with provinces with higher rates of funding 
having lower MPAC rates. One explanation for this finding is that research investment has 
an impact on the culture and quality of the medical workforce. An important factor for 
knowledge utilization is the organizational capacity to engage with and use the evidence.46,47 
The AHFMR natural experiment suggests that investing in a medical research workforce 
may be important in influencing health outcomes. This medical research workforce acts as 
a knowledge translation strategy in itself, with the local researchers having the expertise to 
uptake and implement medical innovation. 
Other indicators such as physician numbers, physician compensation and per capita health 
spending represent quantitative proxy measures for access to treatments. Thus if it were 
the case that technologies, therapies and treatments were available for free to all provinces 
to apply, then we should have seen that variations in measures of access to physicians and 
medical treatment should have explained variations and trends in mortality from treatable 
causes. The lack of compelling correlation on the access measures suggests that the 
variability in declining mortality rates in different provinces cannot be explained by these 
factors. 
The findings from this analysis are limited by the lack of data related to research funding 
and health research workforce. If ability for patients to benefit from the knowledge 
production of research requires local production and/or clinicians who seek out knowledge 
and apply it, then the health research workforce should be correlated with local patient 
outcomes, such as MPAC. Unfortunately, data tracking the health research workforce by 
province is not available. This is a serious limitation for provincial and federal decision 
makers’ informed policy development around assessment of impact and future allocation of 
funding for health research. 
46 
Scott, C. and N. Gall. August, 2006. Knowledge Use in the Calgary Health Region: a Scan of Initiatives That Support Use 
of Evidence in Practice. Final Report. Calgary, AB: Calgary Health Region. 
47 Scott, C., Seidel, J., Bowden,S. and Gall, N. Integrated Health Systems and Integrated Knowledge: Creating Space for 
Putting Knowledge into Action. Healthcare Quarterly. 13: Oct 2009.
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Despite the lack of data available, it is possible that research improves services and 
outcomes for patients because the opportunity to do research attracts a higher quality 
physician, or a different culture of physicians or health care providers that leads to better 
treatment, better practices and innovation in service delivery as a collateral benefit of 
research oriented physicians. Research funding could be considered an alternative to higher 
income, in the sense that offering a contract of income plus research support attracts a 
different type of clinician or professor to the province. 
We suggest that this type of qualitative difference in the physician workforce that 
influences the adoption and use of effective therapies and treatments is likely to have the 
largest impact on MPAC. Consider that the rate of decline in MTC causes seems to be 
more rapid in the provinces with the largest cities. People living in large metropolitan 
areas in Canada have the longest life expectancies and disability-free life expectancies.48 
While this is often attributed to differences in lifestyle and socioeconomic factors, the 
diffusion, dissemination, utilization and integration of medical research regionally is also 
likely to be a factor.49 Medical schools conducting research in larger cities may afford scale 
opportunities for providing treatment that lead to better outcomes, or greater likelihood of 
adoption of new therapies. 
CONCLUSION
The initial AHFMR objective was to both support the recruitment of high quality medical 
researchers and trainees50 as well as support facility upgrades and renovations to improve 
the availability and adequacy of space for medical research to improve the quality of 
health care. In the late 1980’s major contributions to Alberta’s patient care programs were 
identified to be due to attracting clinical and basic scientists with special expertise.51 
52Trustee Dr. Gordon Swann emphasized this stating, “I’ve talked to people in the medical 
community and they say the quality of medical care has been enhanced by the influx of 
medical researchers. The presence of the people makes a quality of health care available to 
48 Shields,M, and Tremblay,S. The Health of Canada’s Communities. Statistics Canada, Catalogue 82-003. Supplement to 
Health Reports, volume 13, 2002.
49 Green,L.W, Ottoson,J.M, García,C, and Hiatt,R.A. Diffusion Theory and Knowledge Dissemination, Utilization, and 
Integration in Public Health. Annual Review of Public Health, Vol. 30: 151 -174 
50 In the 1992 AHFMR annual report it was noted that high housing costs in Alberta was one factor that inhibited the 
recruitment of new personnel to Alberta. 
51 New programs developed and supported by AHFMR funded investigators included examples such as the Alzheimer’s 
Clinic in Calgary, Islet Cell Transplantation program in Edmonton, diagnostic and therapeutic investigations of cardiac 
arrhythmias in both cities, introduction of nuclear magnetic imaging to Alberta, new initiatives in the rehab of stroke 
patients, therapy for autistic children, expertise in infectious disease and AIDSOn the edge of discovery. Third Triennial 
Report on the Alberta Heritage Foundation for Medical Research Part II. Edmonton 1989.
52 The IBR noted that a number of the researchers were expert clinicians in areas not well covered in Alberta; that their 
research was having an impact on the prevention, diagnosis and treatment of disease, and that AHFMR clinical teams 
integrated technical expertise of non-clinical researchers which advanced the quality of patient care. A review of the 
operations of the Alberta Heritage Foundation for Medical Research for the period 1980-1986. Second Triennial Report Part 
II. Alberta Heritage Foundation for Medical Research. Edmonton 1986.
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Albertans never available before, health care as good or better than that found in famous 
clinics like the Mayo clinic”. 53 
The value of AHFMR as a provincial funding agency according to some was the provision 
of long term stable funding which was necessary for “solid progress” in advancing medical 
research in the province. AHFMR president Lionel McLeod argued that to maintain the 
morale and motivation of top quality scientists and trainees attracted to Alberta, and to 
maintain a flow of new young scientists to Alberta, stable funding needed to be assured into 
the next century.54 McLeod cautioned that:
How Alberta will respond to these pressures and opportunities will greatly influence 
our province’s importance to medical research. Failure to respond positively and 
aggressively will signal unwillingness to remain on the leading edge of research and 
patient care and reduce the province’s attractiveness to the best and the brightest 
scientists and their trainees; both those from within and without the province!55 
Our analysis suggests that provincial investment in medical research funding has payback 
in terms of measurable health outcomes. However, knowledge is not transferred without 
cost from producers to users. If patients benefit from medical research knowledge 
production, local production and/or clinicians who seek out knowledge and apply it locally 
is better for health outcomes. While this analysis has important implications for health 
research funding allocations, it also highlights the lack of longitudinal public data available 
on the health research workforce. It is clear that this information is necessary to inform 
future health research funding allocation decisions. 
53 
Alberta Heritage Foundation for Medical Research 4th Annual Report. Edmonton 1984.





This time series data was examined for structural breaks. Structural breaks are an 
economic condition that occurs when there is a changes in how an industry functions or 
operates. A model was developed to detect the structural break points in the trend decline 
in the mortality measure for each province.
𝑙𝑙𝑙𝑙(𝑚𝑚𝑖𝑖𝑖𝑖) = 𝛼𝛼𝑖𝑖 + 𝛽𝛽𝑖𝑖1(𝐷𝐷1 ∙ 𝑇𝑇𝑇𝑇𝑚𝑚𝑇𝑇𝑖𝑖) + 𝛽𝛽𝑖𝑖2(𝐷𝐷2 ∙ 𝑇𝑇𝑇𝑇𝑚𝑚𝑇𝑇𝑖𝑖) + 𝛽𝛽𝑖𝑖3(𝐷𝐷3 ∙ 𝑇𝑇𝑇𝑇𝑚𝑚𝑇𝑇𝑖𝑖) + 𝜀𝜀𝑖𝑖𝑖𝑖  
where 𝑙𝑙𝑙𝑙(𝑚𝑚𝑖𝑖𝑖𝑖)  is the logarithm of three different mortality rates in province i at time 
t; 𝑇𝑇𝑇𝑇𝑇𝑇𝑒𝑒𝑡𝑡 is a time-trend variable taking values as 1, 2, ...33 while t = 1 denotes the first 
year 1979; 𝐷𝐷1 is a dummy variable that equals 1 in year t ≤T1 otherwise it is 0; 𝐷𝐷2 is a 
dummy variable that equals 1 in year T1 < t ≤T2 otherwise it is 0; 𝐷𝐷3 is a dummy variable 
that equals 1 in year t > T2 otherwise it is 0; α and β are parameters of interests. 𝜀𝜀𝑖𝑖𝑖𝑖  is 
the model’s error term which is assumed to have a Normal distribution with mean 0 and 
constant variance.
There are 33 years (1979-2011) in the sample and we assume the structural break dates 
occur in the middle of the sample. Assuming trimming percentage is 15%, a Stata program 
was built to loop over x from 5 to 28 when running model (1). x is then identified as a 
structural break point when the β coefficient estimates are statistically significant. We 
expect α to be negative but the β’s can be positive (trend decline slows after break date) 
or negative (trend decline accelerates after the break date. The model is estimated using 
Generalized Least Squares methods to correct for potential autocorrelation.
TABLE 1 STRUCTURAL BREAKING YEARS FOR THREE MORTALITY RATES
Region Breaking years in MPC Breaking years in MTC Breaking years in MPAC
Alberta 1986, 1990, 2000, 2007 1986, 2000 1986, 1991, 2000, 2007
British Columbia 1986, 1990, 2001, 2007 1983, 1995, 2004 1983, 1987, 2007
Manitoba 1984, 1994, 2003 1993, 1998 1993, 2003
Ontario 1993, 1997, 2001 1989, 1993, 2003 1993, 2003
Quebec 1985, 2000 1990, 1994, 2000, 2005 1985, 2000
Saskatchewan 1983, 1989, 1994, 2008 1987, 1995, 2005 1983, 1989, 1994, 2008
We find multiple structural break points in Alberta the three mortality rates (Table 1)56. For 
Alberta MPC, MTC and MPAC 1986 and 2000 are structural break years. The structural 
break in 1986 is stronger than it is for the breaks in later years. In British Columbia and 
Alberta, the structural break points in MPC, MTC and MPAC are around 1983 -1986. In 
the case of British Columbia, the marginal changes in mortality rate for MPC declines 
faster prior to 1985. For MTC the marginal change in mortality rate declines more slowly in 
Alberta and Manitoba after the structural breaks in the late 80s early 90s whereas in other 
provinces the rate declines faster after the first break points. 
56 Note that MPAC is the sum of MPC and MTC, the results in MPAC (the last column) largely depend upon which mortality 
rate has a stronger structural break than the other.
